New approaches to combat aging and treat autoimmune diseases

Our Pipeline

MyMD has assembled a compelling portfolio of drug candidates to regulate the immunometabolic response through well-defined and efficient clinical pathways. We are using pre-clinical and clinical longevity research and studies to explore the development of drug products that target aging and age-related diseases, and alleviate chronic pain, anxiety, and sleep disorders.

Recently, MyMD announced positive, statistically significant Phase 2 study results in participants with sarcopenia/frailty which showed MYMD-1® reduced TNF-α, IL-6 and sTNFR1, biomarkers which are common to a number of chronic inflammatory diseases, and met all safety and tolerability endpoints. The company is now planning to initiate Phase 3 trials. If approved, MYMD-1® has the potential to be the first drug approved by FDA for the sarcopenia, an age-related decline in muscle mass and physical function which leads to greater risk of hospitalization, disability, and death. MyMD has now submitted and received approval for 3 Investigational New Drug Applications for MYMD-1®, and is advancing these clinical programs in chronic inflammatory conditions including Sarcopenia, RA and Hashimoto’s Thyroiditis

We will also execute studies of Supera-CBD that will enable submission of an Investigational New Drug Application (IND) to the FDA for a Phase 1 clinical trial in epilepsy, chronic pain, and anxiety disorders.

Our leading drug candidates

MyMD is using pre-clinical and clinical longevity research and studies to explore the development of drug products that target aging and age-related diseases, and alleviate chronic pain, anxiety and sleep disorders.

MYMD-1®

MYMD-1® is an orally available, next-generation TNF-alpha inhibitor with potential to provide meaningful therapeutic solutions to patients not served by current TNF-alpha inhibitors. Taken orally, it is easier to administer and possesses a better safety profile than currently approved anti-TNF therapies. Capable of crossing the blood brain barrier, MYMD-1® holds promise in treating CNS-based autoimmune and inflammatory diseases such as multiple sclerosis. It has also demonstrated its potential to slow the aging process and extend healthy lifespan.

Learn More

Supera-CBD

Supera-CBD is a synthetic, non-toxic cannabidiol (CBD) analog that is a more potent CB2 agonist than plant-based CBD. In addition to its potential role in managing addiction, anxiety, chronic pain and seizures, Supera-CBD has also been shown to have anti-inflammatory effects. Supera-CBD is being developed to address anxiety, chronic pain, and seizures and is expected to begin human trials as a therapy for epilepsy, followed by chronic pain.

Learn More

Discovering new and better treatments

We’re partnering with Internationally renowned scientists and academics to validate the promise of our drug candidates as anti-inflammatory and anti-ageing technologies that treat the causes of disease and decline rather than simply focusing on the symptoms. MyMD is working to rapidly advance MYMD-1® and Supera-CBD in clinical trials while identifying and validating additional novel targets.

See the Research
Subscribe to receive MyMD announcements
  • This field is for validation purposes and should be left unchanged.